Liming · In the absence of revenue, the health of the private biotech sector is usually tied up in the purse strings of VCs. In recent years, the funds raised for the sector as a …
Liming · Replidyne: Fare The Well Faropenem…. An unfortunate day indeed as Replidyne (NASDAQ: RDYN) has terminated their licensing deal with Asubio Pharma for its lead drug candidate Faropenem and subsequently is expecting a charge of approximately $4.1M. Recall, Replidyne discontinued enrollment in a late-stage study testing its faropenem medoxomil
Liming · The VIC Fellows Program provides an opportunity for individuals with relevant expertise and interest to learn how to identify and evaluate promising innovation from global sources. We are pleased to highlight the members of the 2020 class of fellows in our ongoing series of interviews, such as this recent discussion with Travis Nemkov, PhD.
Liming · U.S. National Institutes of Health (NIH) sets release date for $30Billion RFP (Request for Proposal) Started by CC-Conrad Clyburn-MedForeSight Aug 19, 2010. 0 Replies 0 Likes
Liming · This article showcases our top picks for the best Colorado based Venture Capital companies. These startups and companies are taking a variety of approaches to innovating the Venture Capital industry, but are all exceptional startups and companies well worth a follow. We tried to pick companies across the size spectrum from cutting edge startups to […]
OnBioVC, the industry leader in organizing and reporting life science private venture financings, provides timely coverage and comprehensive analysis of global bioscience venture capital investment activity. At OnBioVC a free and easy to search database is provided where information queries may be indexed by therapeutic, diagnostic and medical
In 1968, while the semiconductor and biotechnology industries in the San Francisco Bay Area were on the verge of carrying the world into the next technology revolution, the J.F. Shea Co. was working nearby on the San Francisco Bay Area Rapid Transit (BART) system. They were in the perfect position to see and to appreciate the potential future impact of these emerging …
Liming · However, the future is golden (as has been said) for this therapeutic area and one of the companies worth watching in 2007 is Medarex . In 2005 monoclonal antibody drug sales were $14 billion and in 2006 are estimated to be approximately $18 billion, projected to grow to over $30 billion in 5 years.
Liming · A fundamental component to accelerate the region towards achieving a top-tier bio-cluster ranking is a thriving and nurturing bio-entrepreneurial community. BioBeers is designed to function as such an accelerant, where like minded bio-preneurs gather once a month to share ideas, cultivate business relationships and build life long friendships.
Liming · The hard and uncomfortable truth for many hungry and hardworking entrepreneurs is that if they fail at fundraising, there's probably a good reason for it, …
Liming · After a rough 1st quarter, the recently released OnBioVC 2Q09 Trends Analysis shows that life sciences VC funding increased year-over-year by 31%, totaling about $1.71B for 2Q09 vs. $1.18B for 2Q08. Funding for the quarter increased about 20% relative to Q1, which was approximately $1.43B. Not surprisingly, most of the money (almost $1B) went to…
Liming · by Aaron F. Barkoff Orange Book Blog In a 201-page opinion released today, Judge John C. Lifland of the U.S. District Court for the District of New Jersey found all three of Pfizer's patents on Celebrex (celecoxib) valid, enforceable, and infringed by Teva (), who had sought to market a generic version of Celebrex before the patents expire in 2015.
Liming · Oxford Nanopore Announces £70 Million ($109 Million) Fundraising. $59,000,000 Private equity.
Liming · Selecting the right trucks and tippers for a fleet would require assessing the needs of a construction company. Tipper trucks are a vital part of every construction business. A few tipper trucks are an essential component of even the smallest construction companies and other companies that involve carrying freight, scrap, and rubble.
Liming · VentureSource data reveals that ~40% of the Biotech rounds closed in 2011 were Seed/First Rounds. This is up over 2009-2010, but in line with 2007-2008. BioWorld (through their Snapshot) and
View Steven Dupont's profile on LinkedIn, the world's largest professional community. Steven has 8 jobs listed on their profile. See the complete profile on LinkedIn and discover Steven's